Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2020
2019
2018
Profitability Metrics
Gross Margin
89.56%
Operating Margin
88.23%
Net Margin
62.43%
Efficiency Metrics
Revenue per Expense Ratio
8.50
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
2.27%
EPS
1.2100000000
Balance Sheet Analysis
Current Ratio
0.03
Cash Ratio
0.01
Working Capital
$-99.57M
Debt to Equity
0.73
Debt to Assets
41.56%
Equity Ratio
57.01%
Cash Flow Analysis
Operating Cash Flow Ratio
35.25%
Free Cash Flow Ratio
35.25%
CapEx to Revenue
0.00%
Dividends Paid
$14.58M
Stock Buybacks
$142.73K
Total Shareholder Returns
$14.72M
Cash Position Change
8,851.5%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 2.87%
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
194.81%
Net Income
158.75%
EPS
158.74%
Operating Income
195.98%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
1,072.90%
Operating Cash Flow
33.11%
Free Cash Flow
33.11%
Balance Sheet Health
Assets
-3.23%
Debt
7.22%
Book Value per Share
-0.55%
Inventory
-335,100.00%
Shareholder Returns
Dividends per Share
2.87%
Shares Outstanding
-0.12%
Long Term Trends
3Y Revenue/Share
172.16%
5Y Revenue/Share
0.33%
3Y Dividend/Share
-12.63%
5Y Dividend/Share
-54.90%